UBS Group Forecasts Strong Price Appreciation for Addus HomeCare (NASDAQ:ADUS) Stock

Addus HomeCare (NASDAQ:ADUS) had its price objective boosted by UBS Group from $145.00 to $160.00 in a research note issued to investors on Thursday, Benzinga reports. The firm currently has a “buy” rating on the stock. UBS Group‘s price objective indicates a potential upside of 26.17% from the company’s previous close.

Several other equities research analysts also recently issued reports on ADUS. Barclays raised their price target on Addus HomeCare from $96.00 to $101.00 and gave the company an “underweight” rating in a report on Wednesday. Citigroup lowered shares of Addus HomeCare from a “market outperform” rating to a “neutral” rating in a research report on Monday, September 14th. TD Cowen raised their target price on shares of Addus HomeCare from $131.00 to $145.00 and gave the stock a “buy” rating in a research note on Thursday. Weiss Ratings raised shares of Addus HomeCare from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, September 24th. Finally, Royal Bank Of Canada upped their price target on shares of Addus HomeCare from $130.00 to $134.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. Seven analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $134.70.

Addus HomeCare Stock Performance

NASDAQ:ADUS traded down $1.13 on Thursday, hitting $126.81. The company’s stock had a trading volume of 262,556 shares, compared to its average volume of 237,244. The company has a current ratio of 1.69, a quick ratio of 1.69 and a debt-to-equity ratio of 0.05. The stock has a fifty day moving average of $117.35 and a two-hundred day moving average of $106.71. The firm has a market capitalization of $2.37 billion, a P/E ratio of 21.14, a price-to-earnings-growth ratio of 1.80 and a beta of 0.75. Addus HomeCare has a one year low of $87.95 and a one year high of $131.59.

Addus HomeCare (NASDAQ:ADUS) last released its quarterly earnings data on Tuesday, November 3rd. The company reported $1.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.79 by $0.04. The company had revenue of $387.74 million during the quarter, compared to analysts’ expectations of $388.72 million. Addus HomeCare had a return on equity of 10.37% and a net margin of 7.39%. The business’s revenue was up 7.0% on a year-over-year basis. During the same period last year, the firm posted $1.56 earnings per share. Research analysts predict that Addus HomeCare will post 6.33 earnings per share for the current year.

Institutional Investors Weigh In On Addus HomeCare

A number of institutional investors have recently modified their holdings of the business. NFJ Investment Group LLC bought a new position in Addus HomeCare in the 2nd quarter valued at about $29,000. Heritage Family Offices LLP bought a new stake in shares of Addus HomeCare during the 3rd quarter worth approximately $43,000. Parallel Advisors LLC lifted its holdings in shares of Addus HomeCare by 66.3% during the 1st quarter. Parallel Advisors LLC now owns 404 shares of the company’s stock worth $38,000 after acquiring an additional 161 shares during the period. Nisa Investment Advisors LLC boosted its position in shares of Addus HomeCare by 16.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 769 shares of the company’s stock worth $85,000 after acquiring an additional 111 shares in the last quarter. Finally, State of Wyoming acquired a new stake in shares of Addus HomeCare during the 2nd quarter worth approximately $79,000. Institutional investors own 95.35% of the company’s stock.

More Addus HomeCare News

Here are the key news stories impacting Addus HomeCare this week:

• Positive Sentiment: TD Cowen raised its price target to $145 from $131 and reiterated a Buy rating, implying 14.3% upside from the quoted share price. TD Cowen recommendations
• Positive Sentiment: Third-quarter adjusted EPS of $1.83 topped estimates and rose from $1.56 a year earlier. Revenue increased 7% to $387.7 million, roughly in line with expectations, while adjusted EBITDA grew 13.5% to $51.2 million. Third-quarter earnings
• Positive Sentiment: Addus expects its roughly $275 million acquisition of AccentCare’s personal care division to close in the first quarter of 2027 and anticipates a full-year adjusted EBITDA margin in the 13% range. The deal offers a potential growth opportunity, though integration and closing remain ahead. AccentCare update
• Neutral Sentiment: Medicaid-focused home-care providers could benefit if Medicare for All proposals expand coverage or spending on home- and community-based care. However, the legislation is not imminent, faces political hurdles, and does not guarantee higher provider reimbursement. Healthcare stocks and Medicare for All
• Negative Sentiment: Barclays raised its price target to $101 from $96 but maintained an Underweight rating, indicating a bearish view and substantial downside relative to the quoted share price. Barclays recommendations

About Addus HomeCare

Addus HomeCare Inc (NASDAQ: ADUS) provides in-home personal care, hospice and home health services to older adults, people with disabilities and other individuals who need assistance with daily living or medical care. Its services are designed to help clients remain safely and independently in their homes while supporting families and caregivers.

The company’s personal care services include assistance with bathing, dressing, grooming, meal preparation, housekeeping and other activities of daily living.